

Supplementary Table S14. Prostate cancer patient characteristics, median survival, and Multivariate Cox Regression Modeling.

Patient Characteristics: Prostate		LOR	ALP	No Benzo	Overall	P-value
	N	175 (21.3)	118 (14.4)	528 (64.3)	821 (100%)	
Sex	Male	175 (100.0%)	118 (100.0%)	528 (100.0%)	821 (100.0%)	
Grade (Clinical)	I	14 (8.2%)	2 (1.7%)	10 (1.9%)	26 (3.2%)	<.001
	II	61 (35.7%)	35 (30.2%)	212 (40.8%)	308 (38.2%)	
	III	78 (45.6%)	73 (62.9%)	282 (54.2%)	433 (53.7%)	
	IV	3 (1.8%)	1 (0.9%)	8 (1.5%)	12 (1.5%)	
	Not Reported	15 (8.8%)	5 (4.3%)	8 (1.5%)	28 (3.5%)	
Grade (Pathological)	I	9 (5.2%)	1 (0.9%)		10 (1.2%)	<.001
	II	53 (30.8%)	33 (28.2%)	204 (38.9%)	290 (35.7%)	
	III	75 (43.6%)	73 (62.4%)	277 (52.9%)	425 (52.3%)	
	IV	1 (0.6%)		1 (0.2%)	2 (0.2%)	
	Not Reported	34 (19.8%)	10 (8.5%)	42 (8.0%)	86 (10.6%)	
Stage (Clinical)	0			1 (0.2%)	1 (0.1%)	<.001
	I	17 (9.8%)	11 (9.5%)	5 (0.9%)	33 (4.0%)	
	II	61 (35.1%)	46 (39.7%)	414 (78.4%)	521 (63.7%)	
	III	2 (1.1%)	1 (0.9%)	8 (1.5%)	11 (1.3%)	
	IV	25 (14.4%)	10 (8.6%)	19 (3.6%)	54 (6.6%)	
	Not Reported	69 (39.7%)	48 (41.4%)	81 (15.3%)	198 (24.2%)	
Stage (Pathological)	I			2 (0.4%)	2 (0.2%)	<.001
	II	21 (12.1%)	20 (17.1%)	161 (30.5%)	202 (24.7%)	
	III	11 (6.3%)	7 (6.0%)	44 (8.3%)	62 (7.6%)	
	IV	5 (2.9%)	4 (3.4%)	14 (2.7%)	23 (2.8%)	
	Not Reported	137 (78.7%)	86 (73.5%)	307 (58.1%)	530 (64.7%)	
	Overall Survival Indicator	Alive	98 (56.0%)	68 (57.6%)	383 (72.5%)	549 (66.9%)
	Dead	77 (44.0%)	50 (42.4%)	145 (27.5%)	272 (33.1%)	
Progression-Free Survival Indicator	No Progression	87 (49.7%)	63 (53.4%)	339 (64.2%)	489 (59.6%)	0.001
	Progression	88 (50.3%)	55 (46.6%)	189 (35.8%)	332 (40.4%)	

Overall Survival (OS)	Median Surv. (95% CI)	Sample: Prostate	Log Rank P-value
Total	202.2 (188.0, NR)	E=272 C=549 T=821	p= <.001
ALP	155.6 (117.6, 202.2)	E=50 C=68 T=118	
LOR	116.5 (82.2, 136.6)	E=77 C=98 T=175	
No Benzo	NR (200.1, NR)	E=145 C=383 T=528	

Progression-Free Survival (PFS)	Median Surv. (95% CI)	Sample: Prostate	Log Rank P-value
Total	157.3 (146.7, 184.4)	E=332 C=489 T=821	p= <.001
ALP	127.5 (107.0, 181.1)	E=55 C=63 T=118	
LOR	90.6 (67.4, 116.7)	E=88 C=87 T=175	
No Benzo	197.0 (174.1, NR)	E=189 C=339 T=528	

Overall Survival (OS)		
Predictors: Cohort, Clinical Grade, and Clinical Stage		
Cohort	HR (95% CI)	P-value
No Benzo	Ref.	<.0001
ALP	1.464 (1.038 – 2.064)	0.0298
LOR	2.160 (1.589 – 2.936)	<.0001
Progression-Free Survival (PFS)		
No Benzo	Ref.	<.0001
ALP	1.237 (0.899 – 1.702)	0.1916
LOR	1.899 (1.433 – 2.517)	<.0001

E= event, C= censored, T= Total